Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG:3378)
Hong Kong · Delayed Price · Currency is HKD 27.40
-1.44 (-4.99%)
Sep 11, 2026, 4:08 PM HKT
HKG:3378 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 500.29 | 614.4 | 161.21 | 162 |
Trading Asset Securities | 43.99 | 37.76 | 12.67 | 42.36 |
Cash & Short-Term Investments | 544.28 | 652.17 | 173.88 | 204.36 |
Cash Growth | - | 275.07% | -14.92% | - |
Prepaid Expenses | 66.23 | 39.66 | 68.91 | 93.9 |
Other Current Assets | - | - | - | 0.5 |
Total Current Assets | 610.51 | 691.83 | 242.79 | 298.76 |
Property, Plant & Equipment | 15.74 | 19.95 | 24.13 | 24 |
Long-Term Investments | 223.88 | 222.96 | 233.78 | 262.39 |
Other Intangible Assets | 0.34 | 0.42 | 0.45 | 0.56 |
Other Long-Term Assets | 0.15 | 0.33 | 0.33 | 0.53 |
Total Assets | 850.62 | 935.48 | 501.47 | 586.24 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accounts Payable | 11.22 | 18.87 | 12.29 | 12.94 |
Accrued Expenses | 6.5 | 7.6 | 2.8 | 2.56 |
Short-Term Debt | - | 10 | - | - |
Current Portion of Long-Term Debt | - | 20 | - | - |
Current Portion of Leases | 3.39 | 3.52 | 3.17 | 3.2 |
Current Income Taxes Payable | 4.42 | 7.02 | 7.98 | 7.07 |
Other Current Liabilities | 7.32 | 28.11 | 171.2 | 37.11 |
Total Current Liabilities | 32.85 | 95.11 | 197.44 | 62.87 |
Long-Term Debt | 66.8 | 17 | - | - |
Long-Term Leases | 3.55 | 5.35 | 8.66 | 11.83 |
Long-Term Deferred Tax Liabilities | 61.39 | 70.4 | 78.77 | 90.47 |
Other Long-Term Liabilities | - | - | - | 101.49 |
Total Liabilities | 164.59 | 187.86 | 284.87 | 266.66 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 11.93 | 13.62 | 11.79 | 9.53 |
Retained Earnings | - | -203.39 | -72.38 | 0.53 |
Comprehensive Income & Other | 620.58 | 887.51 | 226.83 | 258.07 |
Total Common Equity | 632.51 | 697.74 | 166.24 | 268.13 |
Minority Interest | 53.52 | 49.88 | 50.37 | 51.45 |
Shareholders' Equity | 686.03 | 747.62 | 216.6 | 319.58 |
Total Liabilities & Equity | 850.62 | 935.48 | 501.47 | 586.24 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 73.74 | 55.86 | 11.83 | 15.03 |
Net Cash (Debt) | 470.54 | 596.3 | 162.05 | 189.33 |
Net Cash Growth | - | 267.98% | -14.41% | - |
Net Cash Per Share | 3.70 | 5.04 | 1.37 | 25.95 |
Filing Date Shares Outstanding | 135.86 | 136.22 | 11.79 | 7.3 |
Total Common Shares Outstanding | 135.86 | 136.22 | 11.79 | 7.3 |
Working Capital | 577.66 | 596.71 | 45.35 | 235.89 |
Book Value Per Share | 4.66 | 5.12 | 14.10 | 36.75 |
Tangible Book Value | 632.17 | 697.32 | 165.79 | 267.57 |
Tangible Book Value Per Share | 4.65 | 5.12 | 14.06 | 36.68 |
Machinery | - | 1.94 | 1.19 | 4.1 |
Construction In Progress | - | - | 2.66 | 6.41 |
Leasehold Improvements | - | 11.68 | 8.2 | - |